ISPE board member Dr June Raine will become interim Chief Executive of the UK's Medicines and Healthcare products Regulatory Agency (MHRA) from 20 September 2019. June has been an ISPE board member since August 2013.
Dr Raine has extensive experience and knowledge of the Agency’s work, gained in a number of different licensing and post-licensing roles, and has been Director of the Vigilance and Risk Management of Medicines (VRMM) division since 2006. Her extensive experience includes chairing the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency for six years.
Dr June Raine commented, “I am proud to be asked to lead the Agency at this time and am looking forward to working with colleagues across the health and care sector to protect and promote public health, in the UK and internationally.”
Full press release: https://bit.ly/33ICKMZ
Dr June Raine – biography
Dr Raine qualified in medicine at Oxford University, and undertook postgraduate research leading to an MSc in pharmacology. After general medical posts, her interest in medicine safety led to a career in medicines regulation. She joined the then Medicines Division of the Department of Health in 1985, moving to the Medicines and Healthcare products Regulatory Agency when it was formed in 2003.
Dr Raine worked in several medicines licensing and post-licensing areas, including medical devices, and became Director of the Agency’s Vigilance and Risk Management of Medicines division in 2006. She was chair of the European Pharmacovigilance Risk Assessment Committee (PRAC) on behalf of the European Medicines Agency from 2012 to 2018.